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Background: Xerostomia is a common adverse event of unknown etiology observed dur-
ing pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. 
Objectives: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv 
therapy. 
Patients and Methods: Thirty-one naïve patients with chronic hepatitis C consecutively 
received PegIFN-α2a (180 μg/week) plus Rbv (800–1200 mg/day). The controls were 10 pa-
tients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment 
and follow-up, all patients underwent basal and masticatory stimulated sialometry, 
otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively as-
sess symptoms of oral dryness.
Results: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) 
reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients 
on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001). 
Mean basal (A) and stimulated (B) salivary ﬂow rates (mL/min) progressively decreased 
during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 
0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 follow-
ing PegIFN/Rbv treatment, salivary ﬂow rates were similar to baseline (A, 0.53 at the end 
of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary 
function was unaﬀected in monotherapy patients. 
Conclusions: Rbv causes salivary gland hypofunction in hepatitis C patients receiving 
PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.
Hepat Mon.2011;11(11):918-924. DOI: 10.5812/kowsar.1735143X.733
1. Background
Hepatitis C virus (HCV) eradication is the paradigm of 
pegylated interferon (PegIFN)/Ribavirin (Rbv) therapy 
for chronically infected patients, since it halts hepatitis 
progression, prevents liver failure, and delays the onset 
of hepatocellular carcinoma (1-5). In real life, however, 919  Ribavirin Impairs Salivary Gland Function Aghemo A et al.
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treatment eﬀectiveness is challenged by a signiﬁcant 
rate of side eﬀects that often lessens the acceptability 
of treatment regimens and ultimately modiﬁes patient 
compliance to predetermined treatment schedules (3, 6). 
As a consequence of anemia, neutropenia, and psychiat-
ric symptoms, up to 14% of patients discontinue PegIFN/
Rbv therapy and up to 30% require dose reductions, thus 
potentially compromising the likelihood of a treatment 
response (3, 4, 7). In a signiﬁcant proportion of patients 
enrolled in registration trials, side eﬀects that are not 
hematologic or psychiatric in nature also caused dose 
reductions, ultimately leading to impaired eﬃcacy of an-
tiviral therapy. Among these side eﬀects, xerostomia was 
reported in up to 12% of all patients receiving IFN-based 
therapies, with increasing severity from onset to month 
2–3 of therapy (8). Out of 321 patients with HCV genotype 
2 and 3 consecutively treated with PegIFN/Rbv therapy 
at our center, 92 (29%) reported xerostomia, in terms of 
mouth hyperemia and pain with tongue lesions, result-
ing in a signiﬁcant impairment of the patients’ quality of 
life (9, 10). Unraveling the mechanisms of xerostomia in 
patients receiving PegIFN/Rbv therapy may help improve 
the patients’ quality of life, while also improving treat-
ment adherence through appropriate counseling and 
treatment of symptoms. This will also remain relevant 
in the imminent era of HCV protease inhibitors, where 
optimal adherence will be crucial to maximize eﬃcacy 
and minimize drug resistance (11). To gain insights into 
the respective pathogenic roles of PegIFN and Rbv, we 
dynamically evaluated changes in salivary gland func-
tion in hepatitis C patients receiving PegIFN/Rbv combi-
nation therapy and in patients infected with hepatitis B 
virus (HBV) who received monotherapy with PegIFN only.
2. Objectives
This prospective cohort open-label comparative study 
was carried out in patients with chronic hepatitis C and 
chronic hepatitis B requiring IFN-based therapy. 
3. Patients and Methods 
3.1. Patients
Thirty-one adult patients chronically infected with HCV 
and 10 adult patients chronically infected with HBV, who 
consecutively presented at our center, were oﬀered the 
opportunity to be enrolled in the protocol. All patients 
gave their written informed consent to receive treatment 
and to concurrently undergo ORL evaluation and sialom-
etry. The study was approved by the Institutional Review 
Board of the Department of Internal Medicine of the Uni-
versity of Milan and conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki. All subjects had a liver 
biopsy consistent with chronic hepatitis that had been 
performed in the year preceding treatment. All HCV pa-
tients had at least 1 year of serum positivity for HCV-RNA, 
and exhibited alanine aminotransferase (ALT) levels > 
1.5 times the upper limit of normal. All HBV patients had 
circulating anti-HBe, HBV-DNA levels > 105 cp/mL, and 
ALT levels > 1.5 times the upper limit of normal. Disease 
duration was calculated by considering as the onset of 
infection the date of blood transfusion received prior to 
1992 or the period of drug injection. In patients with an 
unknown source of infection, the date of the ﬁrst abnor-
mal ALT test was arbitrarily taken as the start of infection. 
Exclusion criteria were those generally required for anti-
viral therapy with PegIFN and/or Rbv. Preexisting salivary 
gland disorders such as Sjögren’s syndrome, use of anti-
depressant drugs, and systemic autoimmune disorders 
were also considered as exclusion criteria. 
3.2. Treatment
Patients with chronic hepatitis C were treated with 
PegIFN-α2a (PEGASYS®, Roche, Basel, Switzerland) at a 
ﬁxed dose of 180 g subcutaneously once a week, cou-
pled with either a weight-based (1000 mg/day for  75 kg 
and 1200 mg/day for  75 kg for patients with HCV geno-
type 1 or 4), or ﬁxed (800 mg/day for patients with HCV 
genotype 2 or 3) dose of Rbv. Patients with HBV infection 
received PegIFN-α2a at doses of 180 g subcutaneously 
once a week for 12 months according to an internation-
ally agreed protocol (12). The dose of PegIFN was reduced 
to 135 g whenever neutrophil count decreased under 
0.75 × 109/L. The Rbv dose was reduced by 200 mg in pa-
tients with less than 10 g/L hemoglobin and/or severe 
symptoms of anemia. 
3.3. Deﬁnition of Treatment Response
In HCV patients a sustained virological response (SVR) 
was deﬁned by undetectable HCV-RNA by RT-PCR at week 
24 following treatment. In HBV patients response was de-
ﬁned as normalization of serum ALT and < 2000 cp/mL 
HBV DNA levels measured by a non-PCR assay during the 
ﬁrst 6 months of therapy, and maintained after discon-
tinuation of treatment. 
3.4. Measurements
Serum ALT and aspartate aminotransferase (AST) ac-
tivities were measured by an automated method at 37°C 
(normal values, ≤ 37 and ≤ 41 IU/L, respectively). Commer-
cially available enzyme immunoassays were used to de-
termine the levels of serum hepatitis B surface antigen 
(HBsAg), antibodies to hepatitis B e antigen (anti-HBe), 
and human immunodeﬁciency virus (HIV). Antibodies 
to nuclear, smooth muscle, mitochondrial, and liver and 
kidney microsomal antigens were assayed on rat liver 
and kidney cryostat sections by immunoﬂuorescence. 
Antinuclear antibodies were conﬁrmed on Hep 2 cells. 
Antibody testing for Sjögren’s syndrome (SS-A, SS-Ro, 
SS-B, SS-La), as well as the Schirmer test, were performed 
in all patients. Serum HCV-RNA levels were assessed by 
qualitative RT-PCR assay (COBAS Amplicor HCV test ver-
sion 2.0, Roche Diagnostics) with a detection limit of 50 
IU/mL, at baseline, at weeks 4, 12, 24 (and 48) during treat-
ment, and at weeks 4, 12, and 24 after therapy. HCV was 
genotyped by nested RT-PCR, using universal biotinylat-920  Ribavirin Impairs Salivary Gland Function Aghemo A et al.
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ed primers in the 5′ non-coding region (Line Probe Assay, 
INNO-LIPA HCV 2, Innogenetics, Zwijndrecht, Belgium). 
Serum HCV-RNA was quantiﬁed by the Versant HCV-RNA 
3.0 assay (bDNA 3.0, Bayer Corporation, Emeryville, CA, 
USA), with a sensitivity limit of 615 IU/mL and a dynamic 
range of 615–7,700,000 IU/mL. HBV-DNA determinations 
were performed using a commercially available test (Ver-
sant™ HBV DNA 3.0 Assay, Bayer Healthcare, Tarrytown, 
NY or NJ, USA) with a sensitivity limit of 3.3 log10 copies/
mL. Liver biopsies were performed under ultrasound 
guidance with a 16-gauge Tru-Cut needle (Uro-Cut 16 G, 
TSK, Tokyo, Japan), and read by a single pathologist. Liver 
biopsies were considered to be adequate for ﬁbrosis as-
sessment if they were longer than 15 mm or had more 
than 12 portal tracts. The severity of hepatic inﬂamma-
tion was evaluated by the Ishak score in separate reports 
for grading and staging (13). The maximum score for 
grading was 18, ranging from 0 to 4 for piecemeal necro-
sis, focal necrosis, and portal inﬂammation, and from 0 
to 6 for conﬂuent necrosis. The score for staging ranged 
from 0, representing no ﬁbrosis, to 5 for incomplete cir-
rhosis and 6 for cirrhosis. 
3.5. Sialometry
Glandular saliva was collected in a standardized man-
ner at baseline, at weeks 4, 12, 24, and 48 during treatment 
and, in patients with chronic hepatitis C, at weeks 4, 12, 
and 24 posttreatment. All assessments were performed 
between 8:00 and 10:00 AM in order to minimize ﬂuctua-
tions related to the circadian rhythm of saliva secretion. 
Patients were instructed not to eat, drink, or smoke for 
90 min before the sialometric assessment (14). Unstimu-
lated whole saliva was measured by the spitting method, 
i.e., saliva was allowed to accumulate in the ﬂoor of the 
mouth and the subject spat it out into a graduate test 
tube every 60 s. Unstimulated salivary secretions were 
collected over 5 min. Chewing-stimulated (paraﬃn wax 
1.5 g) whole saliva was measured by the same method. 
Salivary ﬂow was measured in terms of mL/min (15). 
3.6. Signs and Symptoms of Xerostomia
An oral examination was carried out before sialometry 
testing by the same trained physician (M.B.), who was 
blinded to the treatment received by each patient. Oral 
mucosa hyperemia and tongue lesions were scored as vi-
sual hallmarks of hyposialia. At each visit, symptoms of xe-
rostomia were recorded by a questionnaire assessing the 
sensation of dry mouth experienced by the patient (16).
3.7. Statistical Analysis
Distribution of individual characteristics was evaluated 
by simple descriptive statistics, and the results are also 
presented graphically. Analyses of variance for repeated 
measures, with drug treatment as the independent vari-
able and time as the repeated measure, was performed; 
the P-value for the interaction in terms of treatment time 
is presented. Greenhouse–Geisser and Huynh–Feldt ad-
justments, with associated signiﬁcance levels, were cal-
culated, considering that the test of sphericity of the co-
variance matrix was rejected. The change in global mean 
values during treatment with respect to baseline was as-
sessed using the non-parametric Mann–Whitney U test. 
4. Results
4.1. Patients 
Forty-one patients, 31 with HCV infection and 10 with 
HBV infection, were enrolled in the study (Table 1). The 
HCV- and HBV-infected patients were comparable in 
terms of age, ethnicity, body weight, modality of infec-
tion, disease duration, and degree of liver ﬁbrosis. There 
was an excess of males among the HBV-infected patients; 
however, this did not reach statistical signiﬁcance. No 
patient tested positive for non-organ-speciﬁc autoan-
tibodies, or for SS-A, SS-Ro, SS-B, and SS-La antibodies. 
Moreover, the results of the Schirmer test were non-path-
ological in all patients. Overall, 27 HCV patients receiving 
PegIFN/Rbv combination therapy developed symptoms 
of xerostomia, compared to 4 HBV patients receiving Pe-
gIFN monotherapy (87% vs. 40%, P = 0.006). Hyperemia 
or tongue lesions were diagnosed in 30 patients of the 
former group and in 2 of the latter group (97% vs. 20%, P 
< 0.0001). The incidence of signs of dry mouth progres-
sively increased during combination therapy to reach a 
plateau at week 12 of therapy. These signs regressed in all 
but 3 patients during the posttreatment follow-up (Table 
2). In 1 of the 2 HBV patients showing signs of dry mouth, 
the symptoms regressed during treatment, while in the 
remaining patient they disappeared during posttreat-
ment follow-up.
4.2. Salivary Flow Rates
Figures 1A and 1B show mean basal and mean stimu-
lated salivary ﬂow rates, respectively, during treatment, 
HCV HBV P value
Patients, No. 31 10
Male, No. (%) 16 (52) 9 (90) 0.06
Caucasian ethnicity, No. (%) 31 (100) 9 (90) 0.2
Age, y, mean ± SD 52 ± 11 49 ± 7 0.3
Body weight, kg, mean ± SD 70 ± 11 71 ± 8 0.9
Source of infection
Parenteral exposure, No. (%)
IVDA, No. (%)
Unknown, No. (%)
 6 (19)
3 (10)
22 (71)
 3 (30)
0 (0)
7 (70)
0.7
0.6
0.9
Disease duration, mo, 
mean ± SD
202 ± 131 192 ± 121 0.8
Ishak stage
0-4, No. (%)
5 and 6, No. (%)
23 (74)
8 (26)
6 (60)
4 (40)
0.4
0.4
Table 1. Demographic and Clinical Features of the 31 Patients With 
Chronic Hepatitis C and the 10 Patients With Chronic Hepatitis B Enrolled 
in the Study921  Ribavirin Impairs Salivary Gland Function Aghemo A et al.
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Pharyngeal Hyperemia Fissured Epithelium of the Tongue
Baseline 0 0
Treatment duration, W, No. (%)
4
12
24
19 (61)
17 (55)
17 (55)
15 (48)
22 (71)
24 (78)
End of treatment, No. (%) 20 (65) 26 (84)
Post-treatment follow-up, W, No. (%)
4
12
24
16 (52)
9 (29)
3 (10)
11 (35)
6 (19)
1 (3)
Table 2. Incidence of Signs of Dry Mouth at the Otorhinolaryngoiatric Examination in Patients With Chronic Hepatitis C
PegIFN + Ribavirin, mean ± SD PegIFN, mean ± SD P value
Mean Basal
0, W 0.49 ± 0.05  0.45 ± 0.09
0.000 a 
0.002 b 
0.001 c
4, W 0.29 ± 0.04  0.39 ± 0.06
12, W 0.18 ± 0.03  0.36 ± 0.06
24, W 0.17 ± 0.02  0.4 ± 0.07
Absolute diﬀerence T24-T0 -0.33 ± 0.04  -0.05 ± 0.03 0.0004 d
Percent diﬀerence T24-T0 -64.85 ± 3.97 -1.78 ± 6.26 < 0.0001 d
Mean Stimulated
0, W 1.24 ± 0.12 1.13 ± 0.21
0.003 a 
0.02 b 
0.02 c
4, W 0.77 ± 0.05 1.00 ± 0.17
12, W 0.60 ± 0.06 0.92 ± 0.13
24, W 0.53 ± 0.04 0.98 ± 0.14
Absolute diﬀerence T24-T0 -0.74 ± 0.13 -0.15 ± 0.09 0.0014 d
Percent diﬀerence T24-T0 -51.11 ± 5.13 -5.36 ± 6.45 0.0004 d
Table 3. Mean Basal and Stimulated Salivary Flow Rates Stratiﬁed by Treatment Type
a Analysis of Variance for Repeated Measures 
b Analysis of Variance for Repeated Measures with Greenhouse–Geisser correction
c Analysis of Variance for Repeated Measures with Huynh–Feldt correction
d Mann–Whitney U test
stratiﬁed by etiology. In patients receiving combination 
therapy, both mean basal and mean stimulated salivary 
ﬂow rates signiﬁcantly decreased during treatment, with 
values at week 24 being signiﬁcantly lower than baseline 
values (mean basal, 0.49 mL/min vs. 0.17 mL/min, P < 
0.0001; mean stimulated, 1.24 mL/min vs. 0.53 mL/min, 
P = 0.0004). In parallel with increasing mouth dryness, 
salivary ﬂow rates fell to plateau values between week 12 
and week 24 of treatment (mean basal, 0.18 mL/min vs. 
0.17 mL/min; mean stimulated, 0.60 mL/min vs. 0.53 mL/
min). In the 10 patients with chronic hepatitis C treated 
for 48 weeks, no further decrease was observed beyond 
week 24. Patients on PegIFN monotherapy showed no sig-
niﬁcant changes in salivary ﬂow rates (mean basal, 0.45 
mL/min vs. 0.40 mL/min; mean stimulated, 1.13 mL/min 
vs. 0.98 mL/min). At any given time point, the compara-
tive analysis of variance between PegIFN/Rbv and PegIFN 
monotherapy patients showed a signiﬁcant reduction 
in both mean basal and mean stimulated salivary ﬂow 
rates in combination therapy patients (Table 3). During 
posttreatment follow up, PegIFN/Rbv patients showed 
a progressive restoration of mean salivary ﬂow rates, 
with both mean basal (A) and mean stimulated (B) sali-
vary ﬂow rates returning to baseline values by week 24 
(A, 0.53 mL/min vs. 0.49 mL/min; B, 1.19 vs. 1.24 mL/min) 
(Figure 2). Salivary ﬂow rates were not inﬂuenced by to-
tal dose or mean daily dose of Rbv, and did not diﬀer be-
tween patients who achieved SVR and those who failed 
to respond to treatment (Table 4). Moreover, when the 
data were analyzed individually, salivary ﬂow rates were 
not inﬂuenced by the occurrence of Rbv dose reductions 
(data not shown). 922  Ribavirin Impairs Salivary Gland Function Aghemo A et al.
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5. Discussion
Approximately 12% of all patients with HCV infection 
receiving PegIFN/Rbv therapy ultimately develop xero-
stomia, which in turn increases the risk of symptoms 
like dental cavities, nausea, and constipation. Our study 
demonstrates that dry mouth occurring during anti-HCV 
therapy results from a reversible inhibition of salivary 
gland function. At the same time, we show that symp-
toms of mouth dryness are enhanced in HCV patients 
receiving PegIFN/Rbv therapy compared to HBV patients 
receiving monotherapy with PegIFN, indicating a direct 
role of Rbv. Indeed, patients receiving PegIFN monother-
apy showed no salivary dysfunction, while only a few of 
them reported mild and transient symptoms of mouth 
dryness. This is consistent with reports of the eﬀects of 
other drugs such as antidepressants, where, similar to 
our PegIFN monotherapy patients, xerostomia is not di-
rectly caused by salivary gland impairment, as the secre-
tory function of salivary glands is preserved (17). In our 
study, no HCV or HBV patient required treatment with 
antidepressant drugs, ruling out any inﬂuence of these 
drugs on observed salivary ﬂow rates. While we ignore 
the pathogenetic mechanisms of Rbv-induced hyposia-
lia, we may speculate that the changes in salivary ﬂow 
in patients receiving PegIFN/Rbv might result from an 
alteration of exocytosis and/or liquid transport of the 
exocrine glands (18). However, we acknowledge that un-
fortunately our study cannot provide any information 
on this matter, as it was not designed for this endpoint. 
Moreover, we believe that the exact pathogenic mecha-
nisms behind this observation can be unraveled only 
through studies evaluating sialochemistry and eventu-
ally by salivary gland biopsies in patients undergoing Pe-
Basal Salivary Flow, mean ± SD P value Stimulated Salivary Flow, mean ± SD P value
Total ribavirin dose 0.6 0.6
< 145,600, mg
≥ 145,600, mg
-60.88 ± 6.76
-68.56 ± 4.40
-50.95 ± 6.01
-51.28 ± 8.55
Daily ribavirin dose 0.6 0.2
< 12, mg/kg/day 
≥12, mg/kg/day
-67.08 ± 5.65
-62.77 ± 5.72
-48.80 ± 6.41
-53.12 ± 7.98
Sustained virological response 0.2 0.4
No
Yes
-72.55 ± 6.17
-61.39 ± 4.95
-52.64 ± 15.23
-50.50 ± 4.26
Table 4. Percent Change in Basal and Stimulated Mean Salivary Flow Rates at the End of Treatment Versus Baseline
Figure 1. A). Mean Basal Salivary Flow Rates Stratiﬁed by Treatment Regi-
men. B) Mean Stimulated Salivary Flow Rates Stratiﬁed by Treatment Regi-
men.
Figure 2. Mean Salivary Flow Rates in HCV Patients at Baseline, During 
Treatment, and at Post-treatment Follow-ups. 923  Ribavirin Impairs Salivary Gland Function Aghemo A et al.
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gIFN/Rbv therapy. Whatever the underlying mechanisms 
of Rbv-induced hyposialia, the absence of a correlation 
between hyposialia and Rbv dosing discourages Rbv 
dose-adjustment for patients with this undesired eﬀect. 
Moreover, the recognition that salivary gland function is 
only temporarily impaired during PegIFN/Rbv treatment 
encourages counseling and treatment of the symptoms 
of hyposialia with oral hydration or administration of sa-
liva substitutes. Treatment of xerostomia by ORL special-
ists may improve the patient’s quality of life by attenuat-
ing the impairment of the sense of taste, halitosis, and 
interference with functions such as speech, chewing, 
and swallowing (19), thereby not compromising adher-
ence to Rbv dosing. This ﬁnding has important clinical 
implications, since maintaining high Rbv doses will be 
essential in the future to maximize the antiviral eﬀect of 
protease inhibitors of HCV replication, as recently shown 
by Phase II and III trials (20-23). While we acknowledge 
that the present study was conducted on a relatively 
small number of patients, we think that the prospective 
enrollment and the presence of a control group receiv-
ing PegIFN monotherapy allows the data generated here 
to be conﬁdently extrapolated to clinical practice (24). 
Moreover, the risk of intrapatient variations due to age, 
smoking or other unrecognized environmental factors 
was attenuated by the saliva ﬂow tests carried out at dif-
ferent time points, and the risk of interpatient variation 
was eliminated by the 100% compliance of the study par-
ticipants (25). The enrollment of a control group of HCV 
patients receiving Rbv monotherapy in our study would 
have further reinforced our ﬁndings, eﬀectively elimi-
nating the possibility that HCV itself might play a role 
in the development of xerostomia, whilst also allowing 
us to precisely determine which drug is the causal agent 
of salivary gland hypofunction. However, in the study de-
sign process we considered incorporating such a control 
group unethical, due to the minimal to no antiviral eﬀect 
associated with Rbv monotherapy, coupled with the po-
tentially serious adverse events linked to its intake (18). 
In conclusion, this study demonstrates that Rbv is re-
sponsible for xerostomia occurring during anti-HCV 
therapy, causing transient salivary gland hypofunc-
tion that does not appear to be dose-dependent and is 
promptly reverted upon cessation of treatment.
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